Showing 2951 results
-
Story /Radioligand therapy (RLT) has helped change what’s possible in prostate cancer treatment, but Novartis continues to work on the next wave of innovations to bring new options to patients.
-
Press release /Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be…
-
Press release /Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancerKisqali® NATALEE oral presentation to report…
-
Press release /More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12…